IMUXImmunic, Inc.

$138M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$19M

Net Income

-$18M

EPS (Diluted)

$-0.82

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$136M

Total Liabilities

$15M

Stockholders' Equity

$121M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$19M	-$12M	-56.8%
Net Income	-$18M	-$11M	-56.5%

IMUX Q2 2021 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena